Dr. Xiang Li is currently President, Drug Discovery at BioDuro-Sundia, responsible for global drug discovery services at BioDuro-Sundia, including Discovery Chemistry, in vitro Discovery Biology, in vivo Pharmacology, Oncology, Biologics and DMPK. He is an adjunct professor at The School of Pharmaceutical Sciences, Sun Yat-Sen University. Prior to joining BioDuro in 2017, Dr. Li worked at Boehringer Ingelheim (BI) for 21 years dedicated to NCE drug discovery in the Immunology & Inflammation, Cardiovascular and Metabolic disease areas, helping to advance multiple compounds into clinical trials. Dr. Li has in-depth expertise in Structure-Based Drug Discovery (SBDD) and Fragment-Based Lead Discovery (FBLD), and is a recipient of a President’s Award for “Fragment-Based Alternate Lead Discovery” at BI. Dr. Li obtained his D.Phil. (1992) from the University of Oxford with Professor Sir C. M. Dobson, FRS FMedSci under a Sino-British Friendship Scholarship, and completed a CRI Postdoctoral Fellowship in General or Cancer Immunology with Professor P.E. Wright (NAS member) at The Scripps Research Institute. He has a BSc from the University of Science and Technology of China (USTC).